Please try another search
For the three months ended 31 March 2018, Anthera Pharmaceuticals Inc revenues was not reported. Net loss applicable to common stockholders decreased 32% to $9.3M. Lower net loss reflects Fair value of warrant liability in exces decrease from $600K (expense) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$2.03 to -$0.42.
Period Ending: | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -10.97 | -9.26 | -7.91 | -8.66 |
Net Income | -7.72 | -9.67 | -6.31 | 0.31 |
Period Ending: | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 |
---|---|---|---|---|
Total Assets | 8.81 | 3.67 | 8.37 | 14.51 |
Total Liabilities | 3.35 | 9.17 | 8.03 | 9.95 |
Total Equity | 5.46 | -5.5 | 0.34 | 4.56 |
Period Ending: | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -9.38 | -36.9 | -30.64 | -24.44 |
Cash From Investing Activities | 0.36 | 0 | 0 | 0 |
Cash From Financing Activities | 14.91 | 18.25 | 15.87 | 14.75 |
Net Change in Cash | 5.89 | -18.65 | -14.77 | -9.69 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review